EUR 0.27
(0.0%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 19.73 Million EUR | 19.06% |
2022 | 16.57 Million EUR | -17.05% |
2021 | 19.98 Million EUR | 116.37% |
2020 | 9.23 Million EUR | -21.22% |
2019 | 11.72 Million EUR | 22.71% |
2018 | 9.55 Million EUR | -44.06% |
2017 | 17.08 Million EUR | 45.03% |
2016 | 11.77 Million EUR | 31.87% |
2015 | 8.93 Million EUR | -29.69% |
2014 | 12.7 Million EUR | 2.58% |
2013 | 12.38 Million EUR | 10.5% |
2012 | 11.2 Million EUR | 1.31% |
2011 | 11.06 Million EUR | 132.99% |
2010 | 4.74 Million EUR | -36.72% |
2009 | 7.5 Million EUR | 55.95% |
2008 | 4.81 Million EUR | 35.04% |
2007 | 3.56 Million EUR | 73.25% |
2006 | 2.05 Million EUR | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q2 | 19.36 Million EUR | 0.0% |
2023 FY | 19.73 Million EUR | 19.06% |
2023 Q4 | 19.73 Million EUR | 0.0% |
2023 Q2 | 20.44 Million EUR | 0.0% |
2022 Q4 | 16.57 Million EUR | 0.0% |
2022 Q2 | 14.36 Million EUR | 0.0% |
2022 FY | 16.57 Million EUR | -17.05% |
2021 FY | 19.98 Million EUR | 116.37% |
2021 Q2 | 9.4 Million EUR | 0.0% |
2021 Q4 | 19.98 Million EUR | 0.0% |
2020 Q4 | 9.23 Million EUR | 0.0% |
2020 Q2 | 8.25 Million EUR | 0.0% |
2020 FY | 9.23 Million EUR | -21.22% |
2019 Q2 | 7.87 Million EUR | 0.0% |
2019 FY | 11.72 Million EUR | 22.71% |
2019 Q4 | 11.72 Million EUR | 0.0% |
2018 Q4 | 9.55 Million EUR | 0.0% |
2018 FY | 9.55 Million EUR | -44.06% |
2018 Q2 | 6.52 Million EUR | 0.0% |
2017 Q2 | 8.3 Million EUR | 0.0% |
2017 FY | 17.08 Million EUR | 45.03% |
2017 Q4 | 17.08 Million EUR | 0.0% |
2016 FY | 11.77 Million EUR | 31.87% |
2016 Q4 | 11.77 Million EUR | 0.0% |
2016 Q2 | 11.36 Million EUR | 0.0% |
2015 Q2 | 7.73 Million EUR | 0.0% |
2015 FY | 8.93 Million EUR | -29.69% |
2015 Q4 | 8.93 Million EUR | 0.0% |
2014 Q2 | 10.83 Million EUR | 0.0% |
2014 FY | 12.7 Million EUR | 2.58% |
2014 Q4 | 12.7 Million EUR | 0.0% |
2013 Q2 | 11.6 Million EUR | 0.0% |
2013 FY | 12.38 Million EUR | 10.5% |
2013 Q4 | 12.38 Million EUR | 0.0% |
2012 Q2 | 8.04 Million EUR | 0.0% |
2012 FY | 11.2 Million EUR | 1.31% |
2012 Q4 | 11.2 Million EUR | 0.0% |
2011 Q2 | 5.05 Million EUR | 0.0% |
2011 FY | 11.06 Million EUR | 132.99% |
2011 Q4 | 11.06 Million EUR | 0.0% |
2010 FY | 4.74 Million EUR | -36.72% |
2010 Q4 | 4.74 Million EUR | 0.0% |
2010 Q2 | 5.74 Million EUR | 0.0% |
2009 FY | 7.5 Million EUR | 55.95% |
2009 Q4 | 7.5 Million EUR | 0.0% |
2008 FY | 4.81 Million EUR | 35.04% |
2007 FY | 3.56 Million EUR | 73.25% |
2006 FY | 2.05 Million EUR | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
ABIONYX Pharma SA | 6.91 Million EUR | -185.532% |
ABIVAX Société Anonyme | 131.05 Million EUR | 84.94% |
Adocia SA | 31.87 Million EUR | 38.073% |
Aelis Farma SA | 13.08 Million EUR | -50.887% |
Biophytis S.A. | 15.84 Million EUR | -24.525% |
Advicenne S.A. | 24.37 Million EUR | 19.038% |
genOway Société anonyme | 14.45 Million EUR | -36.491% |
IntegraGen SA | 5.97 Million EUR | -230.045% |
Medesis Pharma S.A. | 6.42 Million EUR | -207.119% |
Neovacs S.A. | 3.71 Million EUR | -431.663% |
NFL Biosciences SA | 3.62 Million EUR | -445.091% |
Plant Advanced Technologies SA | 6.78 Million EUR | -190.991% |
Quantum Genomics Société Anonyme | 3.31 Million EUR | -496.235% |
Sensorion SA | 13.22 Million EUR | -49.207% |
Theranexus Société Anonyme | 5.01 Million EUR | -293.446% |
TME Pharma N.V. | 2.78 Million EUR | -608.654% |
Valbiotis SA | 13.7 Million EUR | -43.974% |
TheraVet SA | 1.48 Million EUR | -1229.03% |
Valerio Therapeutics Société anonyme | 20.46 Million EUR | 3.576% |
argenx SE | 402.79 Million EUR | 95.1% |
BioSenic S.A. | 32.26 Million EUR | 38.83% |
Celyad Oncology SA | 9.97 Million EUR | -97.795% |
DBV Technologies S.A. | 38.74 Million USD | 49.062% |
Galapagos NV | 1.56 Billion EUR | 98.736% |
Genfit S.A. | 105.92 Million EUR | 81.367% |
GeNeuro SA | 20.13 Million EUR | 2.005% |
Hyloris Pharmaceuticals SA | 8.61 Million EUR | -129.169% |
Innate Pharma S.A. | 132.29 Million EUR | 85.081% |
Inventiva S.A. | 101.59 Million EUR | 80.573% |
MaaT Pharma SA | 22.46 Million EUR | 12.148% |
MedinCell S.A. | 77.77 Million EUR | 74.623% |
Nanobiotix S.A. | 95.74 Million EUR | 79.386% |
Onward Medical N.V. | 25.69 Million EUR | 23.2% |
Oryzon Genomics S.A. | 25.12 Million EUR | 21.45% |
OSE Immunotherapeutics SA | 59.07 Million EUR | 66.594% |
Pharming Group N.V. | 228.28 Million EUR | 91.355% |
Poxel S.A. | 53.9 Million EUR | 63.385% |
GenSight Biologics S.A. | 34.72 Million EUR | 43.168% |
Transgene SA | 26.51 Million EUR | 25.572% |
Financière de Tubize SA | 123.65 Million EUR | 84.039% |
UCB SA | 6.56 Billion EUR | 99.699% |
Valneva SE | 341.14 Million EUR | 94.215% |
Vivoryon Therapeutics N.V. | 4.54 Million EUR | -334.044% |